why choose us

First received: August 5, 2022

Clinical Trial: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neop

Study Type: Interventional


Official Title: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)

Brief Summary: This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation. Copanlisib may stop the growth of cancer cells by blocking PIK3, a protein needed for cell growth. Researchers hope to learn if copanlisib will shrink this type of cancer or stop its growth.

Read more